Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Key catalysts approach for Orphazyme, Gemini and Immutep.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
Despite missing pretty much all the endpoints of a registrational study, the Danish company insists that it has a chance of approval for a treatment for an incurable…
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.